Aptinyx

graphic image of five staffers leaving a door labeled closed below a sign labeled jobs
Biotech

Molecular Templates halves head count as cash crunch looms

The Bristol Myers-partnered biotech is halving its 222-person team and stopping clinical development of a HER2 drug candidate.
Nick Paul Taylor Mar 31, 2023 6:30am
dominoes fall series fail

Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop

Feb 28, 2023 6:15am
visual of money going into a piggy bank

Drugs up for sale, on the shelf in biotech pipeline clear-outs

Nov 9, 2022 9:40am
Graphic of arrows missing the target

Strike 3: Aptinyx's pain prospect flunks 3rd midphase trial

Aug 12, 2022 8:23am
Digital X-ray brain on blue background neurons

Aptinyx pauses phase 2 trial of higher dose PTSD med

Apr 20, 2022 1:08pm
MRI brain scan

Aptinyx posts phase 2 PTSD win 2 years after diabetes pain flop

Oct 20, 2020 7:17am